Deals Of The Week: Pfizer/Protalix, AstraZeneca/Targacept, Chiesi/Phenomix
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Phenomix And Chiesi Partner For Phase III DPP-4 Drug In Europe
After the deal, Phenomix reports it has an "excellent cash position."
Antibodies Licensed From Trellis Bring MedImmune More Potential RSV Candidates
Using very high throughput screening, Trellis identified antibodies in human blood that had been selected by the immune system to fight the virus.
Pfizer Partners With Protalix On Gaucher Drug Eyeing Lower Cost Plant-Based Production
Pfizer agrees to pay $60 million upfront for rights to taliglucerase, an investigational competitor to Genzyme's Cerezyme.